AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Spautin-1 (MBCQ) (Figure 4, 14) shows potent anticancer activity and improves the efficacy of imatinib mesylate by associating with GSK3β activation-induced apoptosis via inactivating the PI3K/AKT pathway in chronic myeloid leukemia (CML) (Shao et al., 2014).